Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review

被引：1
|
作者：
Elkhooly, Mahmoud [1 ,2 ,3 ]
Bao, Fen [2 ]
Bernitsas, Evanthia [2 ]
机构：
[1] Southern Illinois Univ, Sch Med, Dept Neurol, Springfield, IL 62702 USA
[2] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[3] Minia Univ, Dept Neurol & Psychiat, Al Minya 61519, Egypt
来源：
BRAIN SCIENCES | 2024年 / 14卷 / 01期
关键词：
multiple sclerosis; fatigue; disease modifying therapies; QUALITY-OF-LIFE; RELAPSING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; REAL-WORLD EFFECTIVENESS; GLATIRAMER ACETATE; ORAL FINGOLIMOD; INTERFERON-BETA; NATALIZUMAB; PATIENT; SAFETY;
D O I：
10.3390/brainsci14010004
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system by causing inflammation, demyelination and neurodegeneration. Fatigue is the most prevalent and one of the most disabling symptoms among people with MS (pwMS). Due to its complexity and subjective character, fatigue is still little understood despite its frequent occurrence and severe impact. The potential causes, effects, and treatments of fatigue associated with MS have been extensively studied in recent years. Though the benefits of such a variety of contributions are obvious, there have not been many attempts to evaluate the effect of disease modifying therapies (DMTs) on MS-related fatigue. In this review, we summarize clinical trials and research studies, and we discuss the effect of different DMTs on MS-related fatigue.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients
    Pust, Gesa E. A.
    Poettgen, Jana
    Randerath, Jennifer
    Lau, Stephanie
    Heesen, Christoph
    Gold, Stefan M.
    Penner, Iris-Katharina
    JOURNAL OF NEUROLOGY, 2019, 266 (07) : 1663 - 1673
  • [22] In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients
    Gesa E. A. Pust
    Jana Pöttgen
    Jennifer Randerath
    Stephanie Lau
    Christoph Heesen
    Stefan M. Gold
    Iris-Katharina Penner
    Journal of Neurology, 2019, 266 : 1663 - 1673
  • [23] The impact of Ms-related cognitive Fatigue on Future Brain Parenchymal loss and relapse: a 17-Month Follow-up study
    Sander, Carina
    Eling, Paul
    Hanken, Katrin
    Klein, Jan
    Kastrup, Andreas
    Hildebrandt, Helmut
    FRONTIERS IN NEUROLOGY, 2016, 7
  • [24] Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial
    de Gier, Marieke
    Beckerman, Heleen
    Twisk, Jos W. R.
    Knoop, Hans
    de Groot, Vincent
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (01) : 71 - 79
  • [25] The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme
    Heleen Beckerman
    Lyan JM Blikman
    Martin Heine
    Arjan Malekzadeh
    Charlotte E Teunissen
    Johannes BJ Bussmann
    Gert Kwakkel
    Jetty van Meeteren
    Vincent de Groot
    Trials, 14
  • [26] Interpreting the clinical importance of the relationship between subjective fatigue and cognitive impairment in multiple sclerosis (MS): How BICAMS performance is affected by MS-related fatigue
    Bellew, David
    Davenport, Laura
    Monaghan, Ruth
    Cogley, Clodagh
    Gaughan, Maria
    Yap, Siew Mei
    Tubridy, Niall
    Bramham, Jessica
    McGuigan, Christopher
    O'Keeffe, Fiadhnait
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [27] The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme
    Beckerman, Heleen
    Blikman, Lyan J. M.
    Heine, Martin
    Malekzadeh, Arjan
    Teunissen, Charlotte E.
    Bussmann, Johannes B. J.
    Kwakkel, Gert
    van Meeteren, Jetty
    de Groot, Vincent
    TRIALS, 2013, 14
  • [28] Narrative review based on fingolimod therapy in pediatric MS
    Cinar, Bilge Piri
    Konuskan, Bahadir
    Anlar, Banu
    Ozakbas, Serkan
    SAGE OPEN MEDICINE, 2023, 11
  • [29] Factors that influence adherence with disease-modifying therapy in MS
    Treadaway, Katherine
    Cutter, Gary
    Salter, Amber
    Lynch, Sharon
    Simsarian, James
    Corboy, John
    Jeffery, Douglas
    Cohen, Bruce
    Mankowski, Ken
    Guarnaccia, Joseph
    Schaeffer, Lawrence
    Kanter, Roy
    Brandes, David
    Kaufman, Charles
    Duncan, David
    Marder, Ellen
    Allen, Arthur
    Harney, John
    Cooper, Joanna
    Woo, Douglas
    Stuve, Olaf
    Racke, Michael
    Frohman, Elliot M.
    JOURNAL OF NEUROLOGY, 2009, 256 (04) : 568 - 576
  • [30] Outcome of MS relapses in the era of disease-modifying therapy
    Muriel Stoppe
    Maria Busch
    Luise Krizek
    Florian Then Bergh
    BMC Neurology, 17
12345